JeffreyDavidKlausnerMD

Infectious Disease • Los Angeles, CA

Professor, Preventive Medicine, University of Southern California, Los Angeles, Keck School of Medicine

Join to view full profile

Dr. Klausner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klausner's full profile

Already have an account?

Office
2001 N. Soto Street
3rd Floor
Los Angeles, CA 90033
Phone+1 415-876-8901

Fax+1 867-988-1407

Education & Training

University of WashingtonFellowship, Infectious Disease, 1997 - 1998
NYU Grossman School of MedicineResidency, Internal Medicine, 1991 - 1994
Weill Cornell MedicineClass of 1991

Certifications & Licensure

FL State Medical License 2018 - 2026
MD State Medical License 2022 - 2026
CA State Medical License 1995 - 2025
TX State Medical License 2021 - 2024
WA State Medical License 1997 - 1999
NY State Medical License 1992 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM Start of enrollment: 2005 Oct 01
Completed
Specialized Cognitive-Behavioral Counseling Intervention to Reduce HIV Transmission Risk Behavior in HIV-Infected Men Start of enrollment: 2005 Sep 01
Completed
Not Applicable
Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM Start of enrollment: 2011 Sep 01
Completed
Not Applicable
Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae Start of enrollment: 2016 Oct 19
Completed
Not Applicable
Cefixime for Alternative Syphilis Treatment Start of enrollment: 2018 Sep 03
Completed
Phase 2
Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes Start of enrollment: 2021 Mar 29
Recruiting
Not Applicable
Cefixime Clinical Trial Start of enrollment: 2021 Jun 20
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Linezolid for Syphilis Pilot Study Start of enrollment: 2023 Sep 28
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Clinical Studies Are Needed to Determine the Efficacy of Ceftriaxone and Other Interventions in Addressing Resistant Neisseria gonorrhoeae Infection.
Lao-Tzu Allan-Blitz, Jeffrey D Klausner
Sexually Transmitted Diseases. 2025-01-01
Laboratory evaluation of oral fluid for syphilis screening among clinic users from Lima, Peru.
Jazmin Qquellon, Silver K Vargas, Francesca Vasquez, E Michael Reyes-Diaz, Kelika A Konda
Microbiology Spectrum. 2024-12-10
Prevalence of mpox immunity among the core group and its potential to prevent future large-scale outbreaks.
Lao-Tzu Allan-Blitz, Jeffrey D Klausner
The Lancet. Microbe. 2024-12-01

Press Mentions

Opinion - Should America Rethink the Use of Fluoride in Drinking Water?November 15th, 2024
Sudden Syphilis Retreat in Gay Men Is Most Likely Tied to Preventive Antibiotic UseNovember 12th, 2024
STD Epidemic Slows as New Syphilis and Gonorrhea Cases Fall in USNovember 12th, 2024
Join now to see all

Grant Support

Comprehensive STD Prevention ProjectsNational Center For Hiv, Viral Hepatitis, Stds And Tb Prevention2009
STD Surveillance Network (SSUN)National Center For Hiv, Viral Hepatitis, Stds And Tb Prevention2008–2009
Comprehensive STD Prevention Systems (CSPS)National Center For Hiv, Viral Hepatitis, Stds And Tb Prevention2007–2008